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Background: The clinical course of Cystic Fibrosis (CF) is usually measured using the percent predicted FEV1 and
BMI Z-score referenced against a healthy population, since achieving normality is the ultimate goal of CF care.
Referencing against age and sex matched CF peers may provide valuable information for patients and for
comparison between CF centers or populations. Here, we used a large database of European CF patients to
compute CF specific reference equations for FEV1 and BMI, derived CF-specific percentile charts and compared
these European data to their nearest international equivalents.
Methods: 34859 FEV1 and 40947 BMI observations were used to compute European CF specific percentiles.
Quantile regression was applied to raw measurements as a function of sex, age and height. Results were compared
with the North American equivalent for FEV1 and with the WHO 2007 normative values for BMI.
Results: FEV1 and BMI percentiles illustrated the large variability between CF patients receiving the best current
care. The European CF specific percentiles for FEV1 were significantly different from those in the USA from an earlier
era, with higher lung function in Europe. The CF specific percentiles for BMI declined relative to the WHO standard
in older children. Lung function and BMI were similar in the two largest contributing European Countries (France
and Germany).
Conclusion: The CF specific percentile approach applied to FEV1 and BMI allows referencing patients with respect
to their peers. These data allow peer to peer and population comparisons in CF patients.
Keywords: Cystic fibrosis, Forced expiratory volume in one second, Body mass index, RegistryBackground
The outcome of cystic fibrosis (CF) patients has
improved in recent decades, with mortality less than 5
percent during the first 10 years of life in patients trea-
ted with current multidisciplinary care [1]. However,
disease severity remains variable among children, ado-
lescents and adults [2,3]. In CF, severity is principally
assessed by the decline in lung function because lung
disease still remains the most common cause of death.
Lung function in CF is almost universally calculated as* Correspondence: harriet.corvol@trs.aphp.fr
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reproduction in any medium, provided the orpercent predicted FEV1 referenced against a healthy
population [4,5]. This particular choice reflects a
widely held opinion that achieving normality remains
the ultimate goal of CF care. Irrespective of whether or
not this aspiration is achievable, a limitation of the
current ‘reference against the normal range’ approach
is that it does not provide a ranking of an individual
patient’s status relative to age and sex-matched CF
peers. Similar considerations apply to nutrition, which
must be adequate to maintain lung function [6], or sur-
rogate markers of disease severity calculated from
semi-quantitative screening scales such as the Chrispin
Norman Score that measures lung damage from chest
radiography [7].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Kulich and coworkers converted the absolute FEV1 into
percentiles calculated from a registry of lung function
values in North American CF patients [8]. In a related
manner, McCormick and colleagues converted a chest x-
ray severity score in childhood into population based per-
centiles [9]. Such self-referencing approaches, despite their
calculation from cross sectional data, provide a reference
base that allows the longitudinal tracking of CF disease
outcome and informs on the relative position of a given
patient against his or her peers.
As of now, the CF FEV1 specific percentiles have of
necessity been obtained from US CF patients. It remains
to be established whether these data are appropriate for
European patients with CF. Indeed, there are many dif-
ferences not only in how CF care is organized (for ex-
ample, coverage of neonatal screening, timely referral to
reference centers, variation in standards of care) but also
in the environment between EU nations and across the
Atlantic. Furthermore Kulich analyzed data from 15 years
ago (1994 to 2001) that would not account for recent
progress in CF care. To mitigate against such issues, we
combined data from the European Cystic Fibrosis Soci-
ety Patient Registry (ECFSPR) and data from the current
French CF Modifier Gene Study, to obtain CF reference
percentile equations for lung function and body mass
index that would apply to current European CF patients
and would additionally provide the ranking of an indi-
vidual patient’s status relative to age and sex-matched
CF peers. As a second objective, we examined whether
FEV1 and BMI in CF patients differed between European
countries and across two continents, Europe and North
America (USA).Methods
Patients
We used the multinational ECFSPR as primary source of
data and additional observations from the French CF
Modifier Gene Study (MUCONAT). The former was set
up to “measure, survey and compare CF aspects and
treatments” in European countries [3,10]. Fourteen
countries contributed data to the present study (Austria,
Belgium, Bulgaria, Czech Republic, Denmark, France,
Germany, Greece, Israel, Italy, the Netherlands, Portugal,
Slovenia, Sweden). The coverage of the study relative to
the overall CF population in a given country was esti-
mated using genetic prevalence estimates reported by
Farrell et al. [11], by Efrati et al. [12] for Israel, and by
the French CF national registry for France. Patients’ con-
sent was obtained from every participating country and
all the registry protocols were compliant with the rele-
vant national data protection laws. ECFSPR data at a pa-
tient level were collected on a anonymous basis.The MUCONAT project collects data on prevalent
and incident CF cases. It was approved by the French
ethical committee (CPP n°2004/15) and the information
collection was approved by the CNIL (n°04.404). As for
the ECFSPR, the MUCONAT data were collected on a
strictly anonymous basis. The project is based on the
participation of 38 out of the 49 French CF centers. Pro-
spective data collection started in 2007 for all prevalent
and incident cases.
The following information was extracted from both
databases: FEV1 measurements (in L), country of resi-
dence, CFTR genotype, sex, height, weight and age, BMI.
The ECFSPR covered the period 2004 to 2007, with one
observation per year and per patient. Data for years
2008 to 2010 were obtained for French patients from the
MUCONAT database, so that there was no overlap with
the ECFSPR source. The same patient may have contrib-
uted data over several years; however the current
ECFSPR did not allow reliable data linkage throughout
the years for all the participating countries, so longitu-
dinal aspects were not taken into account. Measurements
in patients after lung transplantation were removed for all
the analyses.
Statistical analysis
The FEV1 percent predicted (FEV1 pp) were esti-
mated according to the Knudson equations [5], and
the BMI z-scores were computed using the WHO
2007 standards [13].
In data contributed to the ECFSPR, some countries
reported the “best” annual FEV1 measurement, while
others, including the 2 largest contributing countries
(France and Germany), reported an unselected meas-
urement. Using the best measurement for computation
leads to overestimation in the CF specific percentile
curves and limit its use to assess patients from unse-
lected measurement. To limit such bias, we transformed
“best” FEV1 values before calculation (see Additional file
1). In short, the correction was computed as follows:
using the French data, where a systematic longitudinal
collection of all FEV1 values is carried out, we deter-
mined, by sex and age, the average difference between
the “best” annual FEV1 and an unselected value of the
same year. A corrected FEV1 measurement was then
obtained by subtracting this value from the reported
FEV1 value in countries reporting best values. As a sen-
sitivity analysis, we also analyzed the data without cor-
rection. This correction was not required for BMI, as
the reported data was not selected.
Quantile regression was used to estimate CF-specific
reference equations for FEV1 and BMI. The q-quantile
(or q-percentile) in a given distribution is the value
below which the smallest q percent of the population is
found: for example, the median is the 50th quantile.
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as a function of covariates [14], whereas standard regres-
sion only models the mean value. Here, we modeled
quantiles of the FEV1 and BMI distribution according to
age and height in European CF patients, separately in
men and women. We used cubic B-splines to capture
the non-linear dependence of FEV1 on age and height,
using 6 nodes to avoid overfit [8]. FEV1 percentiles from
1 to 99% were fitted as a function of age alone, height
alone and of age and height together. BMI quantiles
were estimated as a function of age. Confidence intervals
for quantiles were obtained using the bootstrap.
The difference between the European and the USA
FEV1 CF specific percentiles and between the CF-
specific BMI percentiles and the WHO normative values
was assessed by the difference in area under the curve with
a bootstrap test. Inter country variation was assessed be-
tween the 2 countries contributing the most patients
(France and Germany), one group consisting of smaller
countries with large coverage (> 75%) of CF patients
(Israel, Denmark, Belgium, the Netherlands, Slovenia and
Czech Republic) and a 4th group with other countries (Bul-
garia, Sweden, Portugal, Greece, Austria, Italy). Confidence
intervals for the median percentile in each country was
obtained using bootstrap and corrected for multiple com-
parisons by the Bonferroni rule (4 groups times 3 age




A summary of lung function (FEV1) and nutritional
(BMI) parameters is presented in Table 1 for all CF
patients. The median national coverage was 74%, with a
large range between countries (from 15% to >99%).
Overall, we used 34859 measurements of FEV1 in the
age range 6 to 40 years, and 40947 BMI measures in the
age range 0 to 40 years, corresponding to 16781 patients.
The median female to male ratio was 0.92 (range in the
countries: 0.7 to 1.3) and decreased with age, from 0.93
in the <10 years old to 0.82 in the >35 year olds (Chi-
squared test for trend, P < 0.0001). The number of mea-
surements in adults (> 20 years old) represented 40% of
all reports, with little variation among countries, except
for Bulgaria and Slovenia where only pediatric cases
were available. Median percentage of p.Phe508del homo-
zygosity was 47.8%, although with a wide range from
14% in Israel to 83% in Hungary [15].
Lung function
The mean FEV1 pp showed a decline across age groups,
from 95% for ages 6-13 years and 76% for ages 13-
20 years to 61% for ages 20-40 years. The CF specific
FEV1 percentiles according to age, sex and height areshown in Figure 1. As expected, the median FEV1
increased throughout childhood (almost linearly) and
decreased thereafter. Starting from approximately 1 L at
age 6, irrespective of sex, the median FEV1 increased up
to 3 L in boys at age 18 and to 2.3 L in girls at age 16.
For both sexes, the interquartile range was the largest at
the peak, spanning from 2.2 to 3.7 in boys at age 18, and
1.7 to 2.7 in girls at age 16. The median FEV1 increased
monotonously with height, by approximately 0.25 L with
each additional 10 cm (data not shown).
As shown in Figure 1, we found differences between
the European and the USA percentiles. For example, a
20 year old European male patient 170 cm of height,
with an FEV1 of 3 liters ranked at the 65
th percentile
among US CF patients, but only at the 61st percentile
among European CF patients. The CF percentiles values
according to age or height were higher than those
obtained in the US at the first, second and third quar-
tiles (P < 0.001 for comparison at each quartile). How-
ever, the overall topography of the quantiles paralleled
that of the US with an upwards offset. The correlation
was excellent between the US- and the European-
calculated age and height adjusted CF specific percen-
tiles (r = 0.99, P < 0.001).
Differences between US and European percentiles were
more pronounced in males (the median increased by 0.2 L
on average) than in females (increased by 0.1 L). The differ-
ence in median FEV1 between Europe and the US was also
larger in older patients: 0.1 L difference in the< 15 years
old but 0.3 L in males > 15 years and 0.15 L in females. Fi-
nally, among the young patients (<15 years old), the differ-
ence was greater in the 10th percentile than in the 90th
percentile: in the latter, the curves were almost the same
between the EU and the US.
Nutritional outcome (BMI)
Quantiles of BMI according to age are shown in Figure 2
for males and females. The CF specific BMI profiles
with age were typical of BMI growth curves, but were
lower than the WHO 2007 [16] normative values at all
ages, with important sex differences. For CF boys, the
median BMI remained close to the WHO reference up
to age 10 (i.e. less than 2.5 % difference for the median).
In CF girls, the nutritional status was already impaired
by age 8. The difference to the WHO normative values
was more pronounced in boys than in girls in adoles-
cents and young adults. Overall, at age 20, only one
quarter of young adults with CF were above the median
normative value.
Inter-country comparisons
Figure 3 presents both the age and height adjusted FEV1
and age adjusted BMI percentiles by country and age
group. Importantly, there was no major variation in the















(n) (%) (n) (%) (%) Mean
[range]
(%) Mean± SD Mean± SD
ECFS Patient Registry (2004-2007)
France 5147 89% 14674 47.9 48% 16.7 [0 -
78.4]
34% 74.4 ± 31.8 -0.63 ± 1.07
Germany 5039 74% 19272 48.1 64% 18.1 [0 -
68.2]
39% 75.0 ± 31.6 -0.54 ± 1.09
High coverage
countries
3671 93% 9213 47.4 53% 18.6 [0 -
77.4]
41% 80.1 ± 28.4 -0.35 ± 1.08
Low coverage
countries
1347 18% 3774 48.3 44% 18.3 [0 -
69.0]
40% 81.32 ± 28.0 -0.21 ± 1.08
MUCONAT (2008-2010)
France 1577 39% 3549 47.9 51.8% 20.3 [6.0 -
40.0]
47% 72.9 ± 31.2 -0.53 ± 1.00
Overall 16781 - 50482 47.9 47.8 18.0 [0 -
78.4]
39% 75.7 ± 31.1 -0.52 ± 1.07
* Estimated Coverage derived from prevalence estimates reported by Farell et al., Efrati et al. and the French CF national registry.
** Age> 20 years.
*** FEV1 percent predicted calculated with Knudson equation.
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ing countries (Mann–Whitney-Wilcoxon test for France
and Germany, P = 0.5). For example, the median FEV1
age and height adjusted CF percentile among all patients
was 49% in France and Germany and 52% in other coun-
tries, all very close to the expected 50%. In France and
Germany, the country-level median percentile was close
to 50% in all age classes although somewhat below in
adults (respectively 45% and 47% for France and Ger-
many). In other countries, the observed medians in the 3
age classes were always slightly larger than 50%. More-
over, the observed median percentile in each country
was not correlated with either sample size (P = 0.4),Figure 1 Cystic fibrosis specific FEV1 percentiles according to age and
confidence interval for the median percentile; and the dashed lines correspcoverage (P = 0.4) or percentage of p.Phe508del CFTR
homozygosity (P = 0.4). Similar results were found for p.
Phe508del homozygous patients (data not shown). The
situation was similar for BMI with no discernible pattern
across countries.
Discussion
Achieving normality in lung function or nutritional sta-
tus is the ultimate goal of CF care, even if the possibility
of achieving this ideal remains a moot point given the
multisystem nature of CF and the complexities of the
variable genotype-phenotype relationship [17]. Using a
healthy population as a reference (as is universal withsex, in males (a) and females (b). The grey zone shows the 95%
ond to reference values obtained in US patients.
Figure 2 Cystic fibrosis specific BMI percentiles according to age, in male (a) and female (b) patients. The grey zone shows the 95%
confidence interval for the median percentile. The dashed line shows the normative median from the WHO 2007 definition.
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mality. We propose here that additional information
may be gleaned by referencing CF patients against age
and sex matched CF peers. A large database of European
cystic fibrosis patients was used to compute these refer-
ence percentiles and the software code is available from
the authors on request.
As of today, such CF-specific reference- ranges have
mainly been used for research purposes, for example to
provide a quantitative phenotype for comparing patients
[18]. However, they could also be useful in a given clinic
to either directly compare the performance between CF
centers or to help homogenize patients for inclusion in
clinical trials. This disease-referencing approach couldFigure 3 Age and country cystic fibrosis specific FEV1 (a) and BMI (b)
extend from the first to the last quartile,with the median as a thick line, an
Bonferroni adjusted (12 comparisons) confidence intervals for the country m
not within the confidence interval. Definitions: Infants: 2 to 6 years old; Chi
20 years old.also be useful to physicians and patients to help visualize
the status of a single patient relative to his or her peers.
For example, a longitudinal plot could highlight unusual
worsening of clinical conditions within European CF
framework and help the physician on the need for more
aggressive therapies.
One may worry that referencing CF patients relative to
their peers could lessen physicians’ efforts to improve
CF patients’ health status, if they were satisfied with
their patients’ progress referenced against their peers. In
other words, care must be taken in interpretation such
that the CF specific percentiles should not be interpreted
as “normative” values, but, as discussed above, as a refer-
ence providing additional information. Reassuringly,percentile distributions in European cystic fibrosis patients. Boxes
d whiskers over the whole range. Notches correspond with the 95%
edian, a star indicating that the expected median percentile (50%) is
ldren: 6 to 13 years old; Teenagers: 13 to 20 years old; Adults: over
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equations from US patients since 2005 negatively
impacted CF care as also evidenced by the approach
of McCormick and colleagues who calculated similar
centiles for chest X-ray scores. Furthermore, our
local patient representatives, as required by our con-
sents and ethical practices on the use of such data,
when shown the approach, spontaneously remarked
that they would like to know how they were per-
forming relative to others in Europe. Future studies
will have to determine the impact of providing both
types of reference information, for example in the
case of specific CFTR variants such as G551D-CFTR
which now has a new therapy [19].
Of necessity, it will be imperative to regularly update
the CF specific reference equations to reflect CF care im-
provement. For example, it was reassuring that the Euro-
pean CF-specific FEV1 percentiles were greater than those
computed a few years ago from US CF patients [8]. This
difference was more pronounced in the lower percentiles
at all ages. It is unlikely that this difference results of dif-
ferential mortality, as mortality curves are very similar for
CF patients in large European countries and the US
[20,21]. Better organization of CF care over time may have
led to a larger number of less severe patients included in
registries, therefore leading to improved overall perform-
ance. However, it remains equally likely that changes in
the efficacy of CF care over time is an explanation for the
observed differences given that almost one decade
passed between data collection in the US and the Euro-
pean studies. Significant improvement in the survival
and clinical status of CF patients has been achieved
during this time, by earlier CF diagnosis, better nutri-
tional support and mucus drainage, and better diagno-
sis and treatment of CF-related complications [22]. An
argument in favor of the increased care efficacy is that
the improvement was more pronounced in the patients
with the poorest lung function. In addition, the median
CF specific FEV1 percentile calculated in today’s North-
American patients using the Kulich equations tends to
be above the expected 50th percentile [18].
Using the ECFSPR data permitted analysis of a large
number of measurements obtained from several Euro-
pean countries. Participation to the ECFSPR is on a vol-
untary basis, and the coverage (i.e. the proportion of CF
living population actually included in the registry) ranges
from 15% to >99%, with 9 countries having coverage
greater than 50%. Little selection bias is expected in
countries with large coverage, while it may be significant
in countries where participation is limited to some vol-
untary CF centers. In the latter case, the extent to which
the reported patients’ characteristics are biased rela-
tive to the whole country CF population is unpre-
dictable. However, in our analysis, the estimates werenot substantially affected when we excluded countries
with small coverage.
We computed the CF specific equations so that unse-
lected data could be referenced against these curves.
The FEV1 values reported from countries where only
the best measurement was provided were therefore cor-
rected before analysis. Otherwise, it could have been
the case that the reference curves overestimate the true
status of the CF patients, as a consequence of analyzing
mostly best measurements. However, additional ana-
lysis of the raw data, without corrections, yielded iden-
tical results, showing that the impact was overall small
(see supplemental material). Thus the common as-
sumption that selective reporting of best lung function
can confound data interpretation is not supported by
our findings.
One other result of this study is that the European
CF BMI percentiles were in good agreement with the
normative WHO 2007 curves up to age 7 but lower
thereafter [16]. Despite recommendations to achieve
greater fat and calorie intake, CF children and teen-
agers typically consume similar nutritional amounts
as their healthy peers [23,24]. A positive association
has been observed between a better nutritional status
and a higher pulmonary function, with an inverse re-
lation to morbidity and mortality [6,25]. The BMI of
CF females remained closer to the WHO reference
charts, while it has been reported that they experi-
ence steeper trajectories of health decline [26,27].
In the inter-country comparison, we conjoined coun-
tries with a small number of patients and large coverage,
and all countries with low coverage. This was done to
limit the effect of chance variation that could arise from
small populations. The outcomes in FEV1 were some-
what larger in countries with small coverage. As it is not
possible to rule out selection bias such as a survivor ef-
fect coupled to under diagnosis in these countries, this
result should not be taken as evidence of better out-
comes. The BMI inter-country comparison was less
affected by coverage.
Although the FEV1 CF specific percentiles provide a use-
ful approach for comparing CF patients to their peers, they
do not correct for attrition due to mortality [18]. For ex-
ample, the population median CF percentile is 50% at all
ages, but it is obvious that ranking 50th among 8 years old
CF patients is different from ranking 50th at age 40. The
use of “survival adjusted” CF specific percentiles has been
proposed to measure severity as a quantitative trait irre-
spective of age [18]. More data will be required to fully
adapt this method to the European situation which should
become easier as neonatal screening takes hold across
Europe thus significantly reducing ascertainment bias. In
the meantime, the excellent correlation of the percentiles
found from the European and the US analyses will in
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mon” phenotype in international studies involving
North-America and Europe. This was indeed a critical
limiting factor in earlier analyses [28,29].
Conclusions
To conclude, although achieving normality is the ultim-
ate goal of CF care, separately referencing against age
and sex matched CF peers provides additional informa-
tion to compare CF populations and better illustrates
the range of variability between patients. These new
reference equations also provide tools for computing
quantitative traits for use in genome wide analyses [30].
Ours is only a first step towards the possibility to a fair
comparison of European CF patients and health system
performance. With the future availability of large pheno-
typic databases, it might be possible to apply our ap-
proach in other rare diseases, an emerging priority
across the globe [31].
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Additional file 1: Table S1. Mean difference between Best FEV1
measurement of the year and Unselected FEV1 measurement, according
to sex and age.
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